# Phase 51-2 — Available-data partial OOS

**Status: CLOSED — NO ELIGIBLE CAMPAIGNS / NON-INFORMATIVE FOR PERFORMANCE**

## Scope

This study used only the currently complete frozen option-source interval: **2026-04-21 through 2026-07-21**.

It remained separate from the complete Phase-51 OOS validation window, which is still frozen at **2026-04-21 through 2026-08-04**.

## Frozen candidates

- TT-03 BASE: 300/350/400 geometry.
- TT-03 OTM350: 350/400/450 geometry.

No parameter was selected or tuned.

## Final result

The Phase-51-1 source gate records **14 observed expiries** in the available interval, all Tuesdays. Under the frozen TT-03 rule, entry is exactly three calendar days before expiry. Every scheduled entry date therefore falls on Saturday.

Result for both geometries:

- Observed expiries: **14**
- Eligible expiries: **0**
- Candidate trades: **0**
- Completed trades: **0**
- Performance P&L: **not applicable**
- Coverage: **not applicable because no candidate campaigns exist**
- Promotion: **none**

This is a protocol/calendar outcome, not a strategy P&L failure.

## Workflow evidence

- Final successful Actions run: **37847094909**
- d300 summary: results/phase51/partial_oos/d300/summary.json
- d350 summary: results/phase51/partial_oos/d350/summary.json
- d300 audit: results/phase51/partial_oos/d300/opportunity_audit.json
- d350 audit: results/phase51/partial_oos/d350/opportunity_audit.json
- Report: results/phase51/PHASE51_2_PARTIAL_OOS_REPORT.md

All earlier failed runs remain logged as non-evidence in the Phase-51-2 error log.

## Interpretation

Phase 51-2 provides **no economic evidence for or against TT-03** because the frozen rule creates no eligible fresh-OOS campaigns in the currently available endpoint.

The complete Phase-51 gate is still blocked by the missing 2026-07-28 and 2026-08-04 option data. Therefore Phase 51-3 onward is not advanced from this partial study.

## Next permitted research direction

A separate future research phase may study a calendar-normalized or trading-day interpretation of the three-day rule. Such a mutation must be separately pre-registered and must not be retroactively introduced into Phase 51.
